Payment overview · 2025
General Payments
$493.81
24 reported records · 17 companies
Healthcare provider profile · identity verified
Robert E Jackson, MD
Allopathic & Osteopathic Physicians|Family Medicine · GAFFNEY, SC · NPI 1710965637
Verified facts
What the public records show
CMS Open Payments records show Robert E Jackson, MD received $493.81 in general payments during 2025 across 24 reported records.
Vanda Pharmaceuticals Inc. accounted for 11.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 221 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $54.90 | 11.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.81 | 7.9% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $37.65 | 7.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.37 | 7.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.21 | 7.3% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $33.64 | 6.8% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $33.41 | 6.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $29.06 | 5.9% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $25.56 | 5.2% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $24.86 | 5.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.86 | 4.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.45 | 4.5% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $21.48 | 4.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.22 | 4.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.43 | 4.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.41 | 3.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.49 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $493.81 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $54.90 | 3 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $54.90 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $37.65 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $36.21 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $33.64 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $33.41 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $29.06 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $25.56 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $24.86 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $23.86 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.45 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.22 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| ROTARIX Normalized: rotarix |
Biological | GlaxoSmithKline, LLC. | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 42 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
113 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
221 | 45 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
100 | 25 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 558 | 165 |
| Amlodipine Besylate | Amlodipine Besylate | 454 | 141 |
| Omeprazole | Omeprazole | 418 | 119 |
| Lisinopril | Lisinopril | 412 | 131 |
| Gabapentin | Gabapentin | 397 | 109 |
| Tramadol Hcl | Tramadol Hcl | 377 | 66 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 374 | 61 |
| Lorazepam | Lorazepam | 360 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 355 | 100 |
| Metformin Hcl | Metformin Hcl | 281 | 87 |
| Alprazolam | Alprazolam | 276 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 249 | 68 |
| Furosemide | Furosemide | 248 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 247 | 74 |
| Montelukast Sodium | Montelukast Sodium | 235 | 66 |
| Ozempic | Semaglutide | 221 | 45 |
| Potassium Chloride | Potassium Chloride | 220 | 65 |
| Trazodone Hcl | Trazodone Hcl | 217 | 59 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 206 | 30 |
| Losartan Potassium | Losartan Potassium | 203 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 193 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 187 | 55 |
| Glimepiride | Glimepiride | 177 | 51 |
| Meloxicam | Meloxicam | 167 | 54 |
| Carvedilol | Carvedilol | 166 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 165 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 158 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 144 | 51 |
| Clonazepam | Clonazepam | 139 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 139 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 138 | 36 |
| Pregabalin | Pregabalin | 138 | 32 |
| Testosterone Cypionate | Testosterone Cypionate | 137 | 21 |
| Allopurinol | Allopurinol | 130 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 127 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 125 | 45 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 124 | 34 |
| Sertraline Hcl | Sertraline Hcl | 121 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 115 | 26 |
| Mounjaro | Tirzepatide | 113 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 109 | 26 |
| Eliquis | Apixaban | 100 | 25 |
| Donepezil Hcl | Donepezil Hcl | 99 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 98 | 24 |
| Simvastatin | Simvastatin | 93 | 33 |
| Spironolactone | Spironolactone | 93 | 31 |
| Ezetimibe | Ezetimibe | 91 | 27 |
| Diazepam | Diazepam | 89 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 89 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 27 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 87 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 85 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 74 | 26 |
| Finasteride | Finasteride | 73 | 24 |
| Prednisone | Prednisone | 71 | 42 |
| Doxycycline Hyclate | Doxycycline Hyclate | 70 | 57 |
| Oxycodone Hcl | Oxycodone Hcl | 70 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 69 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 67 | 19 |
| Azithromycin | Azithromycin | 66 | 61 |
| Cephalexin | Cephalexin | 66 | 58 |
| Mirtazapine | Mirtazapine | 65 | 14 |
| Temazepam | Temazepam | 65 | suppressed |
| Glipizide Er | Glipizide | 62 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 62 | 22 |
| Warfarin Sodium | Warfarin Sodium | 61 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 16 |
| Famotidine | Famotidine | 56 | 23 |
| Trulicity | Dulaglutide | 56 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 16 |
| Ibuprofen | Ibuprofen | 54 | 21 |
| Estradiol | Estradiol | 50 | 14 |
| Januvia | Sitagliptin Phosphate | 50 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 49 | 14 |
| Alendronate Sodium | Alendronate Sodium | 47 | 14 |
| Promethazine Hcl | Promethazine Hcl | 47 | 11 |
| Topiramate | Topiramate | 47 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 14 |
| Atenolol | Atenolol | 45 | 12 |
| Benazepril Hcl | Benazepril Hcl | 45 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 44 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 34 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | suppressed |
| Jardiance | Empagliflozin | 42 | 13 |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Synthroid | Levothyroxine Sodium | 40 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 16 |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | 12 |
| Glipizide | Glipizide | 36 | suppressed |
| Lamotrigine | Lamotrigine | 36 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Celecoxib | Celecoxib | 35 | 11 |
| Linzess | Linaclotide | 34 | suppressed |
| Methocarbamol | Methocarbamol | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | 11 |
| Naproxen | Naproxen | 33 | suppressed |
| Repatha Sureclick | Evolocumab | 33 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Bumetanide | Bumetanide | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | 11 |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 13 |
| Acyclovir | Acyclovir | 29 | 11 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 29 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | 11 |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | 14 |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 19 |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 14 |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 11 |
| Tradjenta | Linagliptin | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 12 |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 19 | suppressed |
| Nexletol | Bempedoic Acid | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Triazolam | Triazolam | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Constulose | Lactulose | 13 | suppressed |
| Humalog Mix 50-50 Kwikpen | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 11 |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $493.81 · 24 records | Vanda Pharmaceuticals Inc. | Auvelity, BEXSERO, Dexcom G6 Transmitter, FANAPT, FARXIGA, HETLIOZ, IBSRELA, INGREZZA, JARDIANCE, LINZESS, NURTEC ODT, Ohtuvayre, PEDIARIX, ROTARIX, TRINTELLIX, The Cologuard Plus Collection Kit, VIBERZI, VRAYLAR, Veozah, Wegovy, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error